This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Cipla had earlier invested € 15 million in Ethris in 2022
The demand in Africa for COVID-19 vaccines has declined
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated